MedTrace Logo

Reducing Breathlessness With Dronabinol in COPD Patients

NCT06473701 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-04-17

No results posted yet for this study

Summary

This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).

Conditions

  • COPD
  • Breathlessness
  • Cannabis

Interventions

DRUG

Dronabinol 2.5mg Capsule

Dronabinol 2.5 mg pr capsule. Titration up till 20 mg daily dose.

DRUG

Placebo

Dronabinol-matched placebo capsule containing no active substance.

Sponsors & Collaborators

  • Region of Southern Denmark

    collaborator OTHER

  • Odense Patient Data Explorative Network

    collaborator OTHER

  • University of Southern Denmark

    collaborator OTHER

  • University of Aarhus

    collaborator OTHER

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Ole Hilberg, Prof., MD · Medical Department, Vejle Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2026-09-30
Completion
2026-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06473701 on ClinicalTrials.gov